Urgent.News

the world's headlines, one feed

Editions

Health & Medicine

Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results

New data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI Strengthened executive team and board to bolster late-stage drug development and global commercialization capabilities. VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”)…

We haven't written up this one. Financial Post has the full story — the link below goes straight to it.

Read the original at financialpost.com →

More in Health & Medicine

Parasite-Specific Protein Helps Toxoplasma Adapt to Crowded Conditions

Scientists identified a previously unknown way that the parasite Toxoplasma can adapt to growing in crowded environments of tissue cysts, and identified the protein TgPRO, as a dedicated regulator of…

  • TgPRO protein helps Toxoplasma adapt to crowded conditions
  • Regulates metabolic gene expression in apicomplexans
  • Potential target for antiparasitic drugs inducing oxidative stress